Click here to download our Xarelto questionnaire.
The law in most states provides several personal injury claims for persons who have been seriously injured by a prescription drug. In lawsuits against J&J, the complaints have charged that the company failed to adequately warn physicians and patients of the inability to reverse Xarelto’s potentially dangerous thinning of the blood. Damages sought against pharmaceutical companies for dangerous drug side effects and injuries include:
- Physical pain and suffering, mental anguish and physical impairment;
- Medical expenses, past and future; and
- Loss of earnings and/or earning capacity.
- In the case of a patient’s death, the family of the victim may file a wrongful death action and seek damages.
Xarelto (rivaroxaban)® Bleeding Injuries and Death
The blood thinner Xarelto® has been linked to serious injuries such as:
- internal or uncontrolled bleeding brain hemorrhage
- heart attack
- pulmonary embolism
- deep vein thrombosis and even death
If you or a loved one took Xarelto® and suffered any of these serious injuries or died, you may be entitled to a cash award and compensation for medical expenses. To get help, please contact our Louisiana law offices at 225-928-5053 or you can sign up right here on our website to receive a confidential consultation with us. After submitting your information on our online form, our Xarelto team of legal experts will contact you soon. We will then be able to schedule a time and place for us to meet up and talk with you, at your earliest convenience.
Xarelto® belongs to a class of anticoagulants, or blood thinners, called direct factor Xa inhibitors. Xarelto® (rivaroxaban) was first approved by the FDA in July 2011, and is manufactured by Bayer and Janssen Pharmaceuticals, and is marketed by Janssen Pharmaceuticals.
Xarelto® is a prescription medicine with three primary uses:
to reduce the risk of stroke and blood clots in people with atrial fibrillation;
to treat deep vein thrombosis (blood clots in the legs) and pulmonary embolism (blood clots in the lungs), and to help reduce the risk of those conditions occurring again; and
to reduce the risk of forming a blood clot in the legs and lungs of people who have just had knee or hip replacement surgery.
No Routine Blood Tests Required
While all blood thinners carry a risk of internal bleeding, Xarelto® appears to be associated with a much greater risk than the manufacturers indicated in warnings provided to consumers and the medical community.
Xarelto® was promoted as a convenient alternative to warfarin (Coumadin) because it did not require routine blood tests, close monitoring, or diet and lifestyle changes. However, recent studies indicate that patients with a high risk of bleeding would benefit from blood tests.
No Reversal Antidote Available
While doctors are able to reverse the effects of warfarin if bleeding occurs with vitamin K, Xarelto® bleeding is often uncontrollable due to the lack of an approved reversal agent, thus increasing the risk of serious injury and death.
Blood Clot Related Injuries
Xarelto® is often prescribed to prevent blood clots. Unfortunately, there is a growing amount of evidence linking it to an increased risk of blood clots.
According to a report published by the Institute for Safe Medicine Practices in October 2012, Xarelto® was associated with 356 serious, disabling, or fatal injuries during the first quarter of 2012.
The investigators specifically warned about the risk of Xarelto® blood clots: “The largest identifiable category was serious blood-clot-related injury – most frequently pulmonary embolism – the very events rivaroxaban is intended to prevent.”
Other Injuries May Include:
Abdominal bleeding Gastrointestinal bleeding Kidney bleeding
Adverse Injury Reports
In 2011 and in 2012, adverse effects involving the use of Pradaxa, Xarelto® and warfarin were the most frequently cited anticoagulants in reports to the FDA. A total of 151 deaths from Xarelto® were reported.
In Germany alone, the number of side-effects from Xarelto® has increased. In the first eight months of 2013, German regulators received 968 reports of side effects, including 72 deaths. This is a definite increase over 2012, when a total of 750 adverse reactions were reported, including 58 deaths, in Germany.
Xarelto (generic name: rivaroxaban) was approved in 2011, making it one of the most recent blood thinning medications on the market. The drug is manufactured by Bayer Pharmaceuticals and is marketed by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson. The primary complaint against Xarelto is that it causes uncontrollable bleeding in some users, and many of the country’s top physicians are very concerned.
Pradaxa, a similar blood thinning drug has already had its share of problems, with hundreds of deaths and many thousands of uncontrollable bleeding incidents associated with the drug. Hundreds of lawsuits have been filed against the makers of Pradaxa.
According to legal observers, Xarelto may be headed down the same road as Pradaxa. Many deaths and serious bleeding events have already been blamed on Xarelto. Additionally, The Food and Drug Administration has received reports of serious blood clots among users of Xarelto, despite the fact that the drug is intended to prohibit clotting. At this time, the law office of John J. Pace, APLC is encouraging those users of Xarelto who have developed severe side effects to contact our office and discuss whether you may be entitled to compensation.
Filing a Xarelto Lawsuit
Those who have taken Xarelto and afterwards suffered serious side effects often end up with more medical bills, lost wages and concerns about health care in the future. In addition to financial damages, such victims also have significant pain and suffering, mental anguish and in some cases, a loss of quality of life.
Family members and close friends can also suffer emotional and financial damages because of Xarelto. In extreme cases, such close friends and family members must deal with the incredible loss after the death of their loved-one. In such events, the added burden of medical and funeral costs simply add to the grief.
Patients charge that Xarelto is a dangerous and defective drug because in certain patients it triggers uncontrolled bleeding and other life-threatening complications.
Xarelto was approved in July 2011 to prevent blood clots in patients undergoing knee and hip surgeries, and its use has been expanded to patients with irregular heartbeats or facing a strong likelihood of blood clots in the legs or lungs. It is also used to prevent clots in people who have non-valvular atrial fibrillation. The drug is taken as a pill, and has the chemical name rivaroxaban.
Xarelto Bleeding and Safety Issues
The Xarelto lawsuits allege that the drug can cause major bleeding in the GI tract. Unlike Coumadin, an anti-clotting drug approved over 50 years ago, the concentration of Xarelto in a patient’s blood
cannot be reversed in the case of over-dose or other serious complication. Because 95% of rivaroxaban is bound to protein, even emergency dialysis cannot reduce the concentration of Xarelto in a patient’s blood. Only time can do this. If a Xarelto patient has an emergency bleeding event — such as from a severe injury or major brain or GI tract bleeding — the results can be fatal.
Safety Information about Xarelto on the Web
- Important Safety Information and Warnings about Xarelto
- Warnings and Precautions about Xarelto
- FDA rejects wider use of Xarelto drug